AstraZeneca shows off Farxiga heart failure efficacy at ESC 2019

pharmafile | September 3, 2019 | News story | Manufacturing and Production, Research and Development  

AstraZeneca has revealed new Phase 3 data illustrating that Farxiga (dapagliflozin), in combination with standard of care, met its primary endpoint by reducing the incidence of cardiovascular death and the worsening of heart failure.

The trial is the first of its kind to investigate the efficacy of an SGLT2 inhibitor in treating heart failure in patients with reduced ejection fraction (HFrEF), with and without type-2 diabetes (T2D).

Presented at the ESC Congress 2019 in Paris, the data showed that the combo reduced the risk of cardiovascular (CV) death or worsening of heart failure by 26%, as well as reduced the risk of individual components associated with these events: the risk of a first episode of deteriorating heart failure was reduced by 30%, while risk of death from CV causes was reduced by 18%.

Adt Felloditionally, the trial also saw a “significant improvement” in patient reported outcomes, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score.

“We are very pleased that Farxiga was so effective in our trial – it did all the things we would like any drug to do in heart failure, which are to improve symptoms, reduce hospital admissions and increase survival. Even better, Farxiga was as effective in heart failure patients without diabetes as in those with diabetes,” commented Dr John McMurray, , Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, at the University of Glasgow.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, at AstraZeneca, added: “Farxiga is well established in the treatment of type-2 diabetes, and these exciting new findings offer clinically meaningful insights into the potential of the medicine to reduce the burden of heart failure in patients with and without type-2 diabetes. We are proud to be contributing to the scientific body of evidence during the ESC Congress 2019.”

Matt Fellows

Related Content

No items found

Latest content